BARRY M. BERNSTEIN,RAJEEV M. MENON,KHATRI AMIT,MENSING SVEN,DUTTA SANDEEP,DANIEL E. COHEN,SCOTT C. BRUN,WALID M. AWNI,EMILY O. DUMAS,CHERI E. KLEIN,THOMAS J. PODSADECKI
申请号：
UY34402
公开号：
UY34402A
申请日:
2012.10.19
申请国别(地区):
UY
年份:
2013
代理人:
摘要：
Without interferon Therapies for the treatment of HCV. Preferably, the treatment is of a shorter duration, as no more than 12 Weeks. In One aspect, the Therapies include Managing at least two Direct acting antiviral agents without interferon to a subject with hcv infection.For example, Therapies include administering to a subject a Therapeutic effective amount of a Therapeutic Agent (1, 2 or 3 a Therapeutic Agent and a cytochrome P450 inhibitor (EG, ritonavir) and Ribavirin.Claim 1: a method of treatment for HCV, characterized in that it comprises administering at least two Direct acting antiviral agents (DaaS) and Ribavirin in patients with HCV, where such treatment does not include Administration of interferon to the patient, and the Treatment Lasts for 8, 9, 10, 11 or 12 Weeks.Claim 10: the method of claim 1, wherein said at least two DAAS include PSI bags-7977 and TMC - 435. Claim 18: the method of claim 1, wherein said at least two DAAS include PSI bags-7977 and gs-5885.Claim 22: the method of claim 1, wherein said at least two - and 790052 DAAS include BMS BMS - 650032, and such treatment lasts for 10, 11 or 12 Weeks. Claim 28: the method of claim 1, wherein said at least two include DAAS and daclatasvir INX - 189.Claim 29: a method of treatment for HCV, wherein manage PSI bags-7977 and Ribavirin without prior treatment that a patient is infected with genotype 1 HCV, where such treatment does not include Administration of interferon to the patient, and the tra Treatment lasts 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 Weeks.Terapias sin interferón para el tratamiento de HCV. Preferiblemente, el tratamiento es de una duración más breve, tal como no más de 12 semanas. En un aspecto, las terapia comprenden administrar al menos dos agentes antivirales de acción directa sin interferón a un sujeto con una infección por HCV. Por ejemplo, las terapias comprenden administrar a un sujeto cantidades eficaces de un agente terapéutico 1, un agente t
